Alterity Therapeutics Limited (ATHE), Monday announced that the US Food and Drug Administration has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy, a rare, neurodegenerative disease.
The designation was based on the findings related to ATH434's mechanism of action and the robust and clinically meaningful efficacy from double-blind Phase 2 clinical trial.
The company expects the designation to accelerate the development and review of ATH434.
In the pre-market hours, Alterity's stock is trading at $3.37, down 0.59 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.